Free shipping on all orders over $ 500

(-)-DHMEQ

Cat. No. M11454
(-)-DHMEQ Structure
Synonym:

Dehydroxymethylepoxyquinomicin

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

(-) - DHMEQ (Dehydroxymethylepoxyquinomicin) is an effective and selective and irreversible nf-kappa B inhibitors, covalent binding and cysteine residues. (-)-DHMEQ inhibited nuclear NF-κB translocation and showed anti-inflammatory and anticancer activity.

Chemical Information
Molecular Weight 261.23
Formula C13H11NO5
CAS Number 287194-40-5
Solubility (25°C) DMSO ≥ 40 mg/mL
Storage -20°C, dry, sealed
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Marcin Michalak, et al. Am J Cancer Res. DHMEQ enhances the cytotoxic effect of cisplatin and carboplatin in ovarian cancer cell lines

[2] Jun Ma, et al. Cells. Inhibition of Cellular and Animal Inflammatory Disease Models by NF-κB Inhibitor DHMEQ

[3] Yinzhi Lin, et al. Exp Ther Med. The designed NF-κB inhibitor, DHMEQ, inhibits KISS1R-mediated invasion and increases drug-sensitivity in mouse plasmacytoma SP2/0 cells

[4] Kazuo Umezawa, et al. Oncol Res. Anticancer Activity of Novel NF-kappa B Inhibitor DHMEQ by Intraperitoneal Administration

[5] Yinzhi Lin, et al. Int J Mol Sci. Inhibition of Late and Early Phases of Cancer Metastasis by the NF-κB Inhibitor DHMEQ Derived from Microbial Bioactive Metabolite Epoxyquinomicin: A Review

Related NF-κB Products
Narlumosbart

Narlumosbart is a human IgG4ҡ monoclonal antibody (mAb) that targets Receptor Activating Factor for Nuclear Factor κB Ligand (RANKL) and can be used in studies related to Giant Cell Tumor of Bone (GCTB).

Ac2-26

Ac2-26, an active N-terminal peptide of annexin A1 (AnxA1), attenuates ischemia-reperfusion-induced acute lung injury.

Mitogen-activated protein kinase 1

Mitogen-activated protein kinase 1 (MAPK1) can activate the downstream p38/NF-κB pathway.

IKKγ NBD Inhibitory Peptide

IKKγ NBD Inhibitory Peptide is a highly specific inhibitor NF-κB inhibitor.

Tripeptide-41

Tripeptide-41(CG-Lipoxyn)isa bioactive peptide withreduce fat accumulationeffect and has been reported used as a cosmetic ingredient.

  Catalog
Abmole Inhibitor Catalog




Keywords: (-)-DHMEQ, Dehydroxymethylepoxyquinomicin supplier, NF-κB, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.